Tom Oxley

Tom Oxley is the founding CEO of Synchron, a clinical-stage neurotechnology company developing the world's first endovascular brain-computer interface (BCI). The Stentrode™ platform translates brain activity into digital commands without open-brain surgery, restoring communication and independence for people with paralysis and has implanted its BCI in 10 patients across U.S. and Australian clinical trials. The company was the first to integrate a BCI with Apple devices, enabling patients to control an iPhone, iPad, and Apple Vision Pro using only their thoughts. An Australian-born physician and neuroscientist, Oxley conceived the Stentrode concept in 2007 and led the original development team at the University of Melbourne. He holds an MD from Monash University and a PhD in neuroscience from the University of Melbourne. He practices as a neurointerventionist at Mount Sinai Hospital in New York City, where he has performed over 1,600 endovascular neurosurgical procedures.

He has published over 120 peer-reviewed articles in journals including Nature Biotechnology, NEJM, and The Lancet. Oxley's recognitions include the UNESCO Netexplo Innovation Award, the Global Australian Advance Award, and Synchron has been named to TIME's Best Inventions (2021, 2025) and Bloomberg 50.